Journal of Jilin University(Medicine Edition) ›› 2020, Vol. 46 ›› Issue (01): 96-101.doi: 10.13481/j.1671-587x.20200117
Previous Articles Next Articles
SU Long, ZHANG Yunwei, WANG Zhuo, SONG Fei, QIN Tianxue, GAO Sujun
Received:
2019-10-15
Online:
2020-01-28
Published:
2020-02-03
CLC Number:
SU Long, ZHANG Yunwei, WANG Zhuo, SONG Fei, QIN Tianxue, GAO Sujun. Proliferation inhibition and pro-apoptotic effects of shikonin on human leukemia MV4-11 cells[J].Journal of Jilin University(Medicine Edition), 2020, 46(01): 96-101.
[1] PATEL J P, GÖNEN M, FIGUEROA M E, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia[J]. N Engl J Med, 2012, 366(12):1079-1089. [2] PAPAEMMANUIL E, GERSTUNG M, BULLINGER L, et al. Genomic classification and prognosis in acute myeloid leukemia[J]. N Engl J Med, 2016, 374(23):2209-2221. [3] PASIC I,DA'NA W,LAM W,et al. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML[J]. Eur J Haematol,2019,102(4):368-374. [4] MARCUCCI G, MAHARRY K S, METZELER K H, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia:miR-155 upregulation independently identifies high-risk patients[J]. J Clin Oncol, 2013, 31(17):2086-2093. [5] GERLOFF D,GRUNDLER R,WURM A A,et al. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia[J]. Leukemia,2015,29(3):535-547. [6] KHALIFE J,RADOMSKA H S,SANTHANAM R,et al. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924(Pevonedistat) in FLT3-ITD acute myeloid leukemia[J]. Leukemia,2015,29(10):1981-1992. [7] YOON Y,KIM YO,LIM NY,et al. Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis in HL60 human premyelocytic leukemia cell line[J]. Planta Med,1999,65(6):532-535. [8] MAO X,YU C R,LI W H,et al. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells[J]. Cell Res,2008,18(8):879-888. [9] ZHAO Q L, ASSIMOPOULOU A N, KLAUCK S M, et al. Inhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells[J]. Oncotarget, 2015, 6(36):38934-38951. [10] KOTTARIDIS P D,GALE R E,FREW M E,et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy:analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials[J]. Blood,2001,98(6):1752-1759. [11] THIEDE C,STEUDEL C,MOHR B,et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:association with FAB subtypes and identification of subgroups with poor prognosis[J]. Blood,2002,99(12):4326-4335. [12] FRÖHLING S, SCHLENK R F, BREITRUCK J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:A study of the AML Study Group Ulm[J]. Blood, 2002, 100(13):4372-4380. [13] SCHMID C,LABOPIN M,SOCIÉ G,et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation[J]. Blood,2015,126(17):2062-2069. [14] SONG Y, MAGENAU J, LI Y M, et al. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML[J]. Bone Marrow Transplant, 2016, 51(4):511-520. [15] DEOL A,SENGSAYADETH S,AHN K W,et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis[J]. Cancer,2016,122(19):3005-3014. [16] CANAANI J,LABOPIN M,HUANG X J,et al. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia:A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation[J]. Am J Hematol,2018,93(6):736-744. [17] ZHANG Y Y,MO X D,ZHANG X H,et al. FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients[J]. Bone Marrow Transplant,2019,54(9):1462-1470. [18] LARROSA-GARCIA M, BAER M R. FLT3 inhibitors in acute myeloid leukemia:current status and future directions[J]. Mol Cancer Ther, 2017, 16(6):991-1001. [19] STONE R M, MANDREKAR S J, SANFORD B L, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation[J]. N Engl J Med, 2017, 377(5):454-464. [20] XU L H,GUO Y,CEN J N,et al. Overexpressed miR-155 is associated with initial presentation and poor outcome in Chinese pediatric acute myeloid leukemia[J]. Eur Rev Med Pharmacol Sci, 2015,19(24):4841-4850. [21] RAMAMURTHY R, HUGHES M, MORRIS V, et al. MiR-155 expression and correlation with clinical outcome in pediatric AML:A report from Children's Oncology Group[J]. Pediatr Blood Cancer, 2016, 63(12):2096-2103. [22] ANDUJAR I,RECIO M C,BACELLI T,et al. Shikonin reduces oedema induced by phorbol ester by interfering with IkappaBalpha degradation thus inhibiting translocation of NF-kappaB to the nucleus[J]. Br J Pharmacol,2010,160(2):376-388. [23] CHENG Y W,CHANG C Y,LIN K L,et al. Shikonin derivatives inhibited LPS-induced NOS in RAW 264.7 cells via downregulation of MAPK/NF-kappaB signaling[J]. J Ethnopharmacol,2008, 120(2):264-271. [24] ANDUJAR I,RÍOS J L,GINER R M,et al. Pharmacological properties of shikonin-a review of literature since 2002[J]. Planta Med,2013,79(18):1685-1697. [25] SU L,LIU L H,WANG Y L,et al. Long-term systemic toxicity of shikonin derivatives in Wistar rats[J]. Pharm Biol,2013,52(4):486-490. |
[1] | LI Cheng, LIU Hui, GUO Liang, MA Yunfei, LIU Bailong, DONG Lihua. Radiotherapy combined with gefitinib in treatment of low-grade pulmonary mucoepidermoid carcinoma with EGFR sensitive mutation: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1436-1439. |
[2] | HU Xiao, YU Qiuyan, XU Wen, WANG Chunhong, JIN Lifang, JIN Xin, LI Xiaofeng, WANG Xiuli, YU Xiaoyan, LI Jinghe. Correlation analysis on JAK2V617F mutation and clinical features in patients with myeloproliferative neoplasms and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2019, 45(05): 1106-1112. |
[3] | ZHU Xurong, YAN Yue, DI Zhengli, WANG Tianzhong, HE Fang, WANG Xinlai, GAO Xiaoyu, ZHENG Xuejiao. Expression of miRNA-155 in cerebral cortex tissue of rats with cerebral ischemia-reperfusion injury and its significance [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1144-1149. |
[4] | HANG Min, REN Hongwei, QU Huiming, GENG Long. Clinical significance of IL-17 expression in serum of patients with psoriasis vulgaris and effects of shikonin on IL-6 and IL-23 production in IL-17-stimulated HaCaT cells [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 958-962. |
[5] | YANG Dongyang, LAI Xiaorong, LI Ying, MA Liyu, LUO Gang, LI Zijun, XU Fei, MA Dong. Influence of primary resection and KRAS gene mutation in prognosis of mild symptomatic patients with stage Ⅳ colorectal cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 805-811. |
[6] | WEN Jianping, CUI Yongsheng, ZHANG Xiongji. Expression levels of IL-6 and VEGF in lung adenocarcinoma cells transfected with EGFRL858R and their significances [J]. Journal of Jilin University Medicine Edition, 2016, 42(03): 502-505. |
[7] | LI Qian, LI Jingao, ZHOU Maohua, LIAO Pengjun, PENG Qi, CHEN Jing, CHEN Shaoxian, WEI Shanshan, HUANG Huiting, SHE Miaorong. Relationship between CD56 antigen expression in leukemia cells and prognosis of patients with acute myeloid leukemia [J]. Journal of Jilin University Medicine Edition, 2016, 42(02): 283-289. |
[8] | WEI Shanshan, ZHOU Maohua, LI Jingao, CHEN Jing, CHEN Shaoxian, LI Qian, XIA Pingfang, PENG Qi, SHE Miaorong. Expressions of CD34 and CD38 antigens in leukemia cells of patients with acute myeloid leukemia and their clinical significances [J]. Journal of Jilin University Medicine Edition, 2015, 41(02): 362-368. |
[9] | LIN Xue-jun,YAN Kang-kang,ZHAO Long-yu,BAO Hong-hong,LI Shuang,LIU Xiao-dong,LIU Xin. Meta-analysis on association between smoking and p53 gene mutation in patients with lung cancer [J]. Journal of Jilin University Medicine Edition, 2014, 40(05): 1046-1050. |
[10] | ZHAO Chao-yue,SONG Run-min,QIN Hui,WANG Na,YANG Liu,LI Jiang. Construction and function detection of EMMPRIN glycosylation mutantion plasimid [J]. Journal of Jilin University Medicine Edition, 2014, 40(03): 583-587. |
[11] | ZENG Ya-chang,LI Mu-jun,CHEN Ping,CHEN Yue,CHEN Jing,PANG Li-li. Construction of recombinant vector pEGFP-C2-CD41-42 of CD41-42 mutation β thalassemia and establishment of its stably transfected HeLa cell model [J]. Journal of Jilin University Medicine Edition, 2014, 40(02): 257-260. |
[12] | HU Rui-ping1,CUI Jiu-wei1,LI Wei1,ZHANG Fu-ming,HAN Wei,DU Zhong-hua,HAN Xiu-li,LIU Xiao-ling,LI Hong-bing,XU Wei. Detection of CEBPA gene mutation in patients with newly diagnosed acute myeloid leukemia and its clinical significance [J]. Journal of Jilin University Medicine Edition, 2014, 40(02): 389-394. |
[13] | WANG Huai-dong,ZHANG Xiao-tian,ZHANG Chao,GUAN Shi-hui,DONG Jun-xue,MU Jia,WANG Fang,ZHENG Jing-tong. Application of DNA sequencing technology in study on mechanism of resistance of Escherichia coli under different drug pressure [J]. Journal of Jilin University Medicine Edition, 2014, 40(01): 109-112. |
[14] | SUN Yi-xue,WANG Ai-bing,CHE Guan-yu,LI Zi-yi,ZHANG Xue-ming. Influence of human α-synuclein A30P mutation in neurogenesis in mouse olfactory bulb [J]. Journal of Jilin University Medicine Edition, 2014, 40(01): 74-77. |
[15] | XUE Ping,ZHU Xiao-jing,LIU Xiao-ju,LI Yi-lan,NAN Jia,JIANG Chao,LI Xia-kun. Expression of recombinant truncated human keratinocyte growth factor 1 in insect cells [J]. J4, 2012, 38(4): 633-639. |
|